Chudleigh, Richard A. & Bain, Stephen C.: Semaglutide injection for the treatment of adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2020, 13. vsk, nro 7, s. 675–684. doi:10.1080/17512433.2020.1776108. (englanniksi)
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018-08, 392. vsk, nro 10148, s. 637–649. doi:10.1016/s0140-6736(18)31773-2. ISSN 0140-6736.
Wilding, John P. H. & Batterham, Rachel L. & Calanna, Salvatore & Davies, Melanie & Van Gaal, Luc F. & Lingvay, Ildiko & McGowan, Barbara M. & Rosenstock, Julio & Tran, Marie T. D. & Wadden, Thomas A. & Wharton, Sean & Yokote, Koutaro & Zeuthen, Niels & Kushner, Robert F.: Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 384. vsk, nro 11, s. 989–1002. doi:10.1056/NEJMoa2032183. (englanniksi)
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding: Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018-08, 392. vsk, nro 10148, s. 637–649. doi:10.1016/s0140-6736(18)31773-2. ISSN 0140-6736.
